Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Summary
Oncocyte Corp (Nasdaq: OCX) has announced its participation in BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place on February 11-12, 2025, in Snowbird, Utah. CEO Josh Riggs and CFO Andrea James will represent the diagnostics technology company at the event, where they will conduct one-on-one meetings with potential investors.
Interested investors attending the conference are encouraged to contact BTIG directly to schedule meetings with Oncocyte's leadership team.
Positive
- None.
Negative
- None.
News Market Reaction – OCX
In the trading session that priced this news, OCX gained 14.49%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
February 11-12, 2025, Snowbird, Utah
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors.
Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.
Event: BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025
Dates: February 11-12, 2025
Location: Snowbird, Utah, USA
About Oncocyte
Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
